Jiangsu Hengrui Medicine Co., Ltd.

Shanghai Stock Exchange 600276.SS

Jiangsu Hengrui Medicine Co., Ltd. Market Capitalization on January 14, 2025: USD 38.04 B

Jiangsu Hengrui Medicine Co., Ltd. Market Capitalization is USD 38.04 B on January 14, 2025, a 0.37% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Jiangsu Hengrui Medicine Co., Ltd. 52-week high Market Capitalization is USD 50.60 B on October 08, 2024, which is 33.01% above the current Market Capitalization.
Jiangsu Hengrui Medicine Co., Ltd. 52-week low Market Capitalization is USD 32.73 B on February 02, 2024, which is -13.96% below the current Market Capitalization.
Jiangsu Hengrui Medicine Co., Ltd. average Market Capitalization for the last 52 weeks is USD 39.92 B.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

Shanghai Stock Exchange: 600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

CEO	Mr. Hong Bin Dai
IPO Date	Oct. 18, 2000
Location	China
Headquarters	38 Huanghe Rd Eco & Tech Dev Park
Employees	19,611
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

Key trends

Past 5 years